Yttrium 90 ibritumomab tiuxetan in lymphoma

References

• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
   PubMed Web of Science ®Google Scholar
• Cheson B D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391–398
   PubMed Web of Science ®Google Scholar
• Browman G P, Levine M N, Mohide E A, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995; 13: 502–512
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Wiseman G A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar
• Flinn I W, Kahl B S, Frey E, et al. Dose finding trial of yttrium 90 (90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2004; 104, (abstract)
   Google Scholar
• Fung H C, Forman S J, Nademanee A, et al. A new preparative regimen for older patients with aggressive CD20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): Targeted intensification without increased transplant-related toxicity. Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Besh S, Knox S, et al. Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20 + B-cell follicular/transformed non-Hodgkin's lymphoma. Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Sweetenham J W, Dicke K, Arcaroli J, et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 2004; 104
   Google Scholar
• Tsimberidou A M, Murray J L, O'Brien S, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004; 100: 2195–2200
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Gordon L I, Multani P S, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 2002; 99: 4336–4342
   PubMed Web of Science ®Google Scholar
• Knox S J, Goris M L, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457–470
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Huglo D, Martinelli G, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 2004; 104, (abstract)
   Google Scholar
• Oki Y, Pro B, Delpassand E, et al. A phase II Study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 2004; 104, (abstract)
   Google Scholar
• Radford J A, Ketterer N, Sebban C, et al. Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of a multicenter, phase III clinical trial. Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Liu N S, Keating M J, Albitar M, et al. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Shipley D L, Spigel D R, Carrell D L, et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2004; 22: 6519, (abstract)
   Web of Science ®Google Scholar
• Witzig T E, Wiseman G A, Geyer S M, et al. A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Winter J N, Inwards D J, Spies S, et al. 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses higher than. 4 mCi/kg may be safely combined with high-dose beam and autotransplant: the role for dosimetry. Blood 2004; 2004, (abstract)
   Google Scholar
• Nademanee A, Forman S J, Molina A, et al. High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial. J Clin Oncol 2004; 22: 6504, (abstract)
   Google Scholar
• Vose J M, Bierman P J, Lynch J C, et al. Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT). Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Jacobs S A, McCook B, Torok F, et al. Evaluation of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT). Blood 2004; 2004, (abstract)
   Google Scholar
• Gordon L I, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5: 98–101
   PubMedGoogle Scholar
• Gordon L I, Witzig T E, Murray J L, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular, or transformed B-cell NHL: final results of a randomized controlled trial. Proc Am Soc Clin Oncol 2003; 22: 576, (abstract)
   Web of Science ®Google Scholar
• Wiseman G A, Witzig T E, Murray J L, et al. Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade, follicular, or transformed non-Hodgkin's lymphoma (LG/F/T NHL). Blood 2000; 96(11)A3173
   Google Scholar
• Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19: 478–481
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Czuczman M S, Revell S, et al. Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan. J Clin Oncol 2004; 22: 6696, (abstract)
   Google Scholar
• Witzig T E, Gordon L I, Wiseman G A, et al. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL). 2000; 96(11)A3160
   Google Scholar
• Witzig T E, White C A, Gordon L I, et al. Zevalin radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL). 2001; 98(11)A2539
   Google Scholar
• Witzig T E, White C A, Gordon L I, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263–1270
   PubMed Web of Science ®Google Scholar
• Bartlett N L, Witzig T E, Gordon L, et al. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. 2002; 21: 14a, A51
   Google Scholar
• Emmanouilides C, Murray J L, Vo K, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hogdkin's lymphoma (NHL): results with second-line therapy. Blood 2003; 102, (abstract)
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Emmanouilides C E, Witzig T, et al. Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. 2002; 21: 266a, A1062
   Google Scholar
• Gibson A. Updated results of a phase III trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma. Clin Lymphoma 2002; 3: 87–89
   PubMedGoogle Scholar
• Nabhan C, Peterson L, Kent S, et al. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43: 2145–2149
   PubMed Web of Science ®Google Scholar
• Schilder R, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy (RIT) for low grade, follicular, and CD20 + transformed non-Hodgkin's lymphoma (LG/F/T NHL) is effective even in patients with mild thrombocytopenia and poor prognostic factors. Pro Am Soc Clin Oncol 2001; 20: 2366, A2696
   Google Scholar
• Wiseman G, Leigh B, Dunn W L, et al. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother Radiopharma 2003; 18: 253–258
   PubMed Web of Science ®Google Scholar
• Wiseman G A, White C A, Sparks R B, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181–194
   PubMed Web of Science ®Google Scholar
• Conti P, White C, Pieslor P, et al. Incidence of altered biodistribution detected by indium 111 (111In) imaging prior to yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy: results from a Zevalin imaging registry. Blood 2004; 104, (abstract)
   Google Scholar